BioMarin Exceeds Q2 Revenue and EPS Expectations with $825M in Sales and $1.44 Adjusted EPS

BioMarin reported Q2 adjusted EPS of $1.44, exceeding the consensus of $1.01, and Q2 revenue of $825M, surpassing the consensus of $761.66M. The company's CEO, Alexander Hardy, expressed satisfaction with the performance, citing strong growth, pipeline progress, and successful business development.

Biomarin Pharmaceutical Inc (BMRN) reported robust financial results for the second quarter of 2025, significantly surpassing Wall Street expectations. The company's adjusted earnings per share (EPS) came in at $1.44, well above the forecasted $1.01, marking a 43% surprise [1]. Revenue also exceeded estimates, reaching $825 million compared to the anticipated $761.66 million, an 8.2% surprise [1]. Following the announcement, Biomarin’s stock rose 3.8% in after-hours trading, closing at $58.89 [1].

The company's CEO, Alexander Hardy, expressed satisfaction with the performance, citing strong growth, pipeline progress, and successful business development. "We are very pleased with our Q2 performance across all aspects of the business," Hardy stated [1]. The company's financial highlights included revenue growth of 16% year-over-year, an operating cash flow of $185 million, and a 55% increase in operating cash flow year-over-year [1]. Additionally, the company's VOXZOGO revenue surged 20% year-over-year, reaching $221 million [1].

Biomarin's strong performance is attributed to strategic initiatives such as the acquisition of Inozyme and ongoing investments in digital promotion and field force expansion. The company also reported a 15% year-to-date revenue growth, reflecting its strategic focus on expanding its product portfolio and increasing global market reach [1].

Looking ahead, Biomarin has raised its full-year 2025 revenue guidance to $3.125 billion and increased its non-GAAP EPS guidance to a range of $4.40 to $4.55 [1]. The company is targeting $4 billion in revenue by 2027, with key milestones including the start of a Phase 2/3 study for BMN 333 in the first half of 2026 and the anticipated VOXZOGO hypochondroplasia data in 2026 [1].

Investors can access detailed analysis and financial tips through InvestingPro's Pro Research Report, available exclusively to subscribers [1].

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-biomarin-beats-q2-2025-estimates-stock-rises-93CH-4169010